Business US
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics – Business Wire
- Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics Business Wire
- Bristol Myers to buy startup Orbital Therapeutics, building out cell therapy pipeline statnews.com
- BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence Fierce Biotech
- Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push CNBC
- Bristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition Endpoints News
